Yüksel Ürün· @DrYukselUrun · X·· 22 小时前评分70
正文 · 原文
Another reminder that immunotherapy is not a universal solution.
KEYNOTE-B49 highlights the need for better patient selection.
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26
269 浏览 · 9 赞 · 4 转发 · 1 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgKeynote B49 - pembrolizumab does not work much in this Hr positive Her2 negative MBC population( endocrine resistant ) @myESMO @dr_yakupergun @OncoAlert #esmo26在 X 查看被引用的帖子
帖内回复
- Michiel Strijbos@StrijbosMichiel
@DrYukselUrun @mirrorsmed @myESMO @OncoAlert @OpenMedicineHQ Not every tumor’s a superhero waiting for its IO cape… but with the right biomarker sidekick, we still get some cape-worthy wins! 🦸♂️🔬✨ #SelectWisely #KEYNOTEB49
来源：Yüksel Ürün · x.com